Schizophrenia, a complex psychiatric disorder with profound cognitive and behavioral symptoms, affects approximately 1% of the global population. A significant barrier to effective treatment has been the incomplete understanding of how genetic and neural circuit alterations contribute to cognitive deficits, such as disordered thinking and impaired sensory integration. The team at MIT, led by Guoping Feng, focused on elucidating the mechanisms behind impaired belief updating—a cognitive hallmark hypothesized to underlie psychosis—using a sophisticated genetic mouse model.

The study centers on a mutation in the grin2a gene, which encodes a subunit of the NMDA receptor, an essential glutamate receptor integral to synaptic plasticity and neuronal communication. Previous large-scale genomic screenings identified grin2a as one of the top genes harboring mutations with a strong association to schizophrenia. Given the gene’s role in synaptic signaling, the researchers posited that alterations in grin2a could disrupt neural circuits crucial for cognitive flexibility and updating beliefs based on sensory input.

To investigate this, the researchers engineered mice carrying the grin2a mutation and subjected them to behavioral paradigms designed to probe cognitive adaptation to changing reward contingencies. In one key experiment, mice were trained to choose between two levers: one that offered a higher reward but required more effort, and another providing a smaller reward at less cost. Wild-type mice adapted their choices as the task parameters evolved, shifting preference from the high-effort lever to the low-effort one when it became more advantageous. Contrastingly, mutant mice exhibited prolonged indecision and a delayed switch in preference, indicative of impaired belief updating and reduced cognitive flexibility.

Delving deeper into the neural dynamics, the team employed functional ultrasound imaging alongside electrophysiological recordings to pinpoint disruptions within the mediodorsal thalamus, a crucial hub interfacing with the prefrontal cortex to regulate executive functions and decision-making processes. In mice carrying the grin2a mutation, neuronal activity in this thalamic region was diminished and exhibited aberrant patterns correlating with their maladaptive decision behaviors. This supports the theory that dysfunctional thalamocortical circuits impair the integration of new sensory evidence into existing cognitive frameworks.

Taking a step further, the scientists utilized optogenetics to selectively stimulate mediodorsal thalamus neurons in mutant mice, effectively rescuing the deficits in adaptive behavior. By activating these neurons with precisely timed light pulses, the mice began to demonstrate decision-making patterns more akin to their wild-type counterparts. This pioneering intervention highlights the therapeutic potential of targeting discrete neural circuits to ameliorate specific cognitive symptoms of schizophrenia.

The implications of this study extend beyond the grin2a mutation itself. Although only a minority of schizophrenia patients carry mutations in this gene, the identified thalamocortical circuit deficits may represent a convergent pathway through which disparate genetic abnormalities manifest similar cognitive impairments. This circuit-based perspective advocates for a shift in therapeutic strategies from focusing solely on individual genes to modulating neural network function.

Moreover, this research provides a mechanistic explanation for psychosis-related belief disturbances long hypothesized in psychiatric literature. The concept that patients with schizophrenia overweigh prior beliefs at the expense of new sensory information is now traceable to concrete neurogenetic and circuit-level dysfunctions, bridging the gap between high-level cognitive theories and molecular neuroscience.

The study was made possible by a multidisciplinary approach combining behavioral neuroscience, advanced imaging, genetic engineering, and optogenetic technology. This integrative methodology sets a new standard for modeling complex psychiatric disorders and exploring potential interventions in preclinical settings.

Funding support from institutions including the National Institutes of Mental Health and the Stanley Center for Psychiatric Research underscored the importance and collaborative nature of this work. As the researchers continue to dissect the components of this thalamocortical circuit, they aim to identify druggable targets that could restore circuit function and improve cognitive outcomes for patients living with schizophrenia.

Ultimately, this research paves the way for novel treatments that go beyond symptomatic relief toward addressing the neural dysfunctions that underlie the debilitating cognitive and perceptual disturbances of schizophrenia. It marks a significant step forward in psychiatry’s quest to unravel the complex biology of mental illness and develop precision medicine approaches tailored to individual neural circuitry deficits.

Subject of Research: Animals
Article Title: Reduced mediodorsal thalamus activity underlies aberrant belief dynamics in a genetic mouse model of schizophrenia
News Publication Date: 18-Mar-2026
Web References: http://dx.doi.org/10.1038/s41593-026-02237-9
Image Credits: MIT
Keywords: Neuroscience, Psychiatric disorders, Schizophrenia, Brain, Human brain, Genetics, Cognitive impairment, Mediodorsal thalamus, NMDA receptor, grin2a gene, Optogenetics, Thalamocortical circuit

Schizophrenia, a complex and multifaceted psychiatric disorder characterized by hallucinations, delusions, cognitive impairments, and emotional dysregulation, has long challenged neuroscientists and clinicians alike. Despite its prevalence, affecting approximately 1% of the global population, the precise neural alterations underlying schizophrenia remain incompletely understood. Morphometric similarity, a neuroimaging metric that quantifies structural similarity across brain regions, has emerged as a powerful tool to evaluate brain network integrity and aberrations in neuropsychiatric conditions. Deviations in morphometric similarity reflect atypical cortical organization which is thought to underpin dysfunctional brain connectivity observed in schizophrenia patients.

The new study, led by Liu, Yang, Chen, and their collaborators, employed state-of-the-art neuroimaging techniques combined with individualized morphometric analyses to assess the extent to which risperidone modulates these structural abnormalities. Through longitudinal MRI assessments, the researchers tracked alterations in cortical morphometric similarity metrics before and after risperidone treatment in schizophrenia cohorts, revealing a marked normalization effect. Crucially, the extent of reduction in morphometric similarity deviation correlated with improvements in clinical symptomatology, highlighting the therapeutic relevance of these neural changes.

What truly sets this research apart is its integrative multi-omics approach. Beyond imaging, the team incorporated cortical transcriptomic data—essentially gene expression profiles from affected brain regions—to probe molecular mechanisms potentially driving morphometric alterations and their remediation with risperidone. Their analysis identified distinct gene expression patterns linked to synaptic plasticity, neurotransmitter pathways, and neuroinflammatory processes, which appear intricately tied to the morphometric reorganization observed in patients post-treatment.

This convergence of morphometric and transcriptomic evidence suggests risperidone’s action extends beyond symptomatic relief and touches fundamental biological substrates, including modulation of gene networks associated with cortical structure and function. Understanding how psychopharmacological agents recalibrate these gene expression profiles offers unprecedented insight into molecular pathways exploitable for next-generation therapeutics targeting schizophrenia’s core pathology.

Moreover, the concept of individualized morphometric similarity deviation advances the precision medicine paradigm within psychiatry. Treatment responses can be idiosyncratic, and the ability to quantify patient-specific brain network deviations provides a quantitative biomarker to track disease progression and tailor interventions accordingly. This methodology heralds a move away from broad-spectrum antipsychotic use towards more refined, mechanism-based strategies aligned with each patient’s unique neuroanatomy and molecular signature.

The broader implications of these findings resonate deeply within neuroscience and clinical psychiatry. They validate morphometric similarity deviation as a critical biomarker for schizophrenia, endorse risperidone’s neural reparative properties, and illuminate transcriptomic landscapes that could serve as drug targets. Future trials integrating these biomarkers may optimize dosing protocols and predict response trajectories more accurately, reducing trial-and-error prescribing and enhancing patient outcomes.

This research also invigorates ongoing discussions about the neurodevelopmental versus neurodegenerative nature of schizophrenia. The reversible normalization of morphometric abnormalities post-risperidone administration suggests plasticity within affected circuits, countering notions of irreversible brain deterioration and supporting rehabilitative therapeutic approaches. It invites reexamination of schizophrenia’s clinical staging, urging clinicians to intervene early to harness this neuroplastic potential.

Furthermore, the identification of transcriptomic alterations associated with treatment response broadens our understanding of schizophrenia as a disorder deeply rooted in gene-environment interactions. It lays groundwork for combining pharmacotherapy with epigenetic or gene expression-modulating interventions in the future, potentially enabling synergistic effects that improve long-term functional recovery.

The technological tools implemented in this study—high-resolution MRI, advanced neuroanatomical mapping, and integrative transcriptomics—highlight the increasing sophistication of contemporary psychiatric research. Their successful application exemplifies the power of interdisciplinary methodologies to unravel psychiatric illness complexities, a trend expected to drive the field forward in coming years.

Importantly, this work underscores the need for continued research into antipsychotic mechanisms at multiple biological scales, from synaptic physiology to systemic brain network dynamics. Such multilevel understanding is critical to design drugs with enhanced specificity and fewer side effects, given that current antipsychotics often carry substantial adverse burdens impacting patient adherence and quality of life.

In sum, the findings by Liu, Yang, Chen, et al. provide a compelling narrative about the neural substrates modulated by risperidone in schizophrenia, combining morphometric neuroimaging and molecular neuroscience to offer a holistic view of treatment effects. This integrative approach exemplifies the future of psychiatric research, where clinical, imaging, and genomic data converge to optimize diagnosis, monitoring, and therapeutics. As science marches toward unraveling the enigma of schizophrenia, studies such as this inch us closer to truly personalized medicine—a hope long cherished but only now becoming achievable.

Ultimately, these advances highlight that despite schizophrenia’s complexity, targeted interventions can recalibrate dysfunctional brain architecture and associated molecular abnormalities. Such discoveries renew optimism for patients and caregivers, reinforcing the potential of science to transform devastating mental illnesses from chronic burdens into manageable conditions with tangible recovery prospects. As further investigations build on this foundation, the prospect of precision psychiatry grounded in neuroimaging and cortical transcriptomics will reshape clinical paradigms and improve countless lives worldwide.

Subject of Research: The effect of risperidone on morphometric similarity deviation in schizophrenia and its association with cortical transcriptomic patterns.

Article Title: Risperidone reduces individualized morphometric similarity deviation in schizophrenia and associates with cortical transcriptomic patterns.

Article References: Liu, L., Yang, M., Chen, J. et al. Risperidone reduces individualized morphometric similarity deviation in schizophrenia and associates with cortical transcriptomic patterns. Schizophr (2026). https://doi.org/10.1038/s41537-025-00724-9

Image Credits: AI Generated